Quebec-based omega-3 drug developer Acasti Pharma (Acasti Pharma Stock Quote, Chart, News TSXV:ACST) is keeping its "Top Pick" status from Echelon … [Read more...] about Acasti Pharma keeps “Top Pick” Status at Echelon for 2020
Life Sciences
Content brought to you by:
The Cantech Letter Life Sciences section is brought to you by Relay Medical Corp. (CSNX:RELA). Relay is in the business of commercializing innovative technologies, protected by issued and pending patents, in the medical diagnostics and research field with an emphasis on In Vitro Diagnostics (IVD) and Point of Care Testing (POCT). Click on the logo for more info...
HLS Therapeutics gets a price target hike at Stifel Canada
Based on its strong growth profile for both sales and EBITDA, Stifel Canada analyst Justin Keywood on Tuesday raised his target price for HLS … [Read more...] about HLS Therapeutics gets a price target hike at Stifel Canada
Biotech stocks are ready to roar, this fund manager says
There’s good value to be had in 2020 from biotech stocks, says Eden Rahim of Next Edge Capital, who thinks that, in particular, Montreal-based … [Read more...] about Biotech stocks are ready to roar, this fund manager says
HLS Therapeutics has a winner in Vascepa, Stifel says
On the back of a US FDA label expansion for Vascepa, Canadian specialty pharma company HLS Therapeutics (HLS Therapeutics Stock Quote, Chart, News … [Read more...] about HLS Therapeutics has a winner in Vascepa, Stifel says
Profound Medical will have a transformative 2020, says Raymond James
Medical device company Profound Medical (Profound Medical Stock Quote, Chart, News TSX:PRN) is already up 22 per cent over the last two weeks but … [Read more...] about Profound Medical will have a transformative 2020, says Raymond James
Is Knight Therapeutics worth owning?
Specialty pharma company Knight Therapeutics (Knight Therapeutics Stock Quote, Chart, News TSX:GUD) saw its share price spike in October on news of a … [Read more...] about Is Knight Therapeutics worth owning?
It’s time to buy Theratechnologies, Mackie Research says
Specialty pharma company Theratechnologies (Theratechnologies Stock Quote, Chart News TSX:TH) has been on an 18-month slide but the stock is looking … [Read more...] about It’s time to buy Theratechnologies, Mackie Research says
Oncolytics Biotech has loads of upside, says Echelon Wealth
Compared to its oncology drug peers, Canadian cancer biologics developer Oncolytics Biotech (Oncolytics Biotech Stock Quote, Chart, News TSX:ONC) is a … [Read more...] about Oncolytics Biotech has loads of upside, says Echelon Wealth
Medexus Pharmaceuticals is a must-own stock, says Mackie Research
Mackie Research analyst André Uddin is staying bullish on specialty pharma company Medexus Pharmaceuticals (Medexus Pharmaceuticals Stock Quote, … [Read more...] about Medexus Pharmaceuticals is a must-own stock, says Mackie Research
Antibe Therapeutics is a junior biotech stock with promise: Echelon
Drug developer Antibe Therapeutics (Antibe Therapeutics Stock Quote, Chart, News TSXV:ATE) is taking longer than expected to get to Phase 2 data for … [Read more...] about Antibe Therapeutics is a junior biotech stock with promise: Echelon
